Eli Lilly announced on Friday that it has more than doubled its investment in its Lebanon, Ind., manufacturing site with a $5.3 billion commitment that will expand its capacity to make active pharmaceutical ingredients (API) for tirzepatide (Mounjaro and Zepbound) as well its pipeline drugs.
Source: Drug Industry Daily